Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Olema Pharmaceuticals Inc

Company price
7.02 USD 0.00(0%)
Last update at 2026-11-20T21:00:00Z
VOLUME
1256470
Market Cap
855.73M

Momentum Score

…

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.88
Low
7.35
High
52 Week Price Range
6.65
Low
36.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
7.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-52.74%
Net Debt
-47.11M
ROCE
-33.73%
Diluted EPS TTM
-2.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -162.45M -129.47M -96.66M -104.79M -71.10M
Net income -162.45M -129.47M -96.66M -102.59M -70.89M
Selling general administrative 21.00M 17.74M 18.82M 24.71M 20.39M
Selling and marketing expenses - - 0.38M - -
Gross profit - -0.39M -0.38M - -
Reconciled depreciation 0.49M 0.39M 0.39M 0.36M 0.16M
Ebit -162.45M -129.47M -96.66M -107.34M -71.49M
Ebitda -161.96M -129.08M -96.28M -106.99M -71.10M
Depreciation and amortization 0.49M 0.39M 0.38M 0.36M 0.40M
Non operating income net other - - - 2.20M 0.40M
Operating income -178.70M -142.26M -104.96M -106.99M -71.49M
Other operating expenses 178.70M 142.26M 104.96M 106.99M 71.49M
Interest expense - - - 0.36M 0.23M
Interest income 16.22M 12.68M 5.75M 2.23M 0.44M
Net interest income 16.22M 12.68M 5.75M 2.23M 0.44M
Income tax expense - -0.00M - -2.20M -0.21M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 178.70M 142.26M 104.96M 106.99M 71.49M
Cost of revenue - 0.39M 0.38M - -
Total other income expense net 16.25M 12.78M 8.31M 2.20M 0.40M
Net income from continuing ops -162.45M -129.47M -96.06M -104.79M -71.10M
Net income applicable to common shares - - - -104.79M -71.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 533.43M 450.98M 276.94M 215.65M 295.94M
Intangible assets - 0.68M - - -
Other current assets 5.96M 2.27M 4.03M 4.48M 0.22M
Total liab 54.87M 42.02M 23.05M 18.10M 11.38M
Total stockholder equity 478.56M 408.96M 253.90M 197.55M 284.57M
Other current liab 41.42M 36.09M 17.93M 15.16M 0.38M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -597.56M -435.11M -305.63M -208.98M -104.19M
Other assets - - 0.00M 2.77M 0.54M
Cash 48.30M 139.48M 68.54M 23.70M 287.25M
Total current liabilities 51.80M 41.76M 21.62M 16.55M 9.02M
Current deferred revenue - - - - 7.69M
Net debt -47.11M -138.05M -66.12M -21.14M -283.96M
Short term debt 1.12M 1.17M 0.99M 1.01M 0.93M
Short long term debt total 1.19M 1.43M 2.42M 2.56M 3.29M
Other stockholder equity 1075.49M 843.92M 559.18M 408.33M 388.90M
Property plant equipment - - - 1.48M 4.72M
Total current assets 515.45M 438.47M 266.51M 208.90M 287.25M
Net tangible assets - - - 197.55M 284.57M
Short term investments 457.14M 294.61M 193.27M 180.72M 273.44M
Net receivables 4.06M 2.12M 0.67M 0.32M 0.13M
Long term debt 3.00M - - - -
Inventory - -4.02M - -0.32M -
Accounts payable 9.25M 4.46M 2.70M 0.37M 0.02M
Accumulated other comprehensive income 0.62M 0.14M 0.35M -1.81M -0.15M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -208.98M -104.19M
Non currrent assets other 16.83M 9.76M 8.14M 2.77M 3.98M
Non current assets total 17.98M 12.51M 10.43M 6.75M 8.70M
Capital lease obligations 1.19M 1.43M 2.42M 2.56M 3.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -155.76M -93.53M 42.40M 91.84M -273.86M
Change to liabilities - - - 7.37M -0.68M
Total cashflows from investing activities -155.76M -93.53M -4.85M 91.48M -275.44M
Net borrowings 3.00M 0.00M - - -
Total cash from financing activities 211.30M 268.82M 133.41M 0.48M 1.39M
Change to operating activities - - - 2.67M 3.51M
Net income -162.45M -129.47M -96.66M -104.79M -71.10M
Change in cash -91.18M 70.94M 44.84M 9.89M -324.74M
Begin period cash flow 139.48M 68.54M 23.70M 13.81M 338.55M
End period cash flow 48.30M 139.48M 68.54M 23.70M 13.81M
Total cash from operating activities -146.72M -104.35M -83.73M -82.06M -50.69M
Issuance of capital stock 205.39M 266.29M 129.74M - 0.00M
Depreciation 0.49M 0.39M 0.38M 0.36M 0.16M
Other cashflows from investing activities - -0.16M 0.01M - -
Sale purchase of stock 1.03M - - 0.48M 1.39M
Other cashflows from financing activities 211.30M 2.53M 3.68M 0.15M 0.67M
Change to netincome - - - 18.83M 17.41M
Capital expenditures 0.00M 0.16M 0.00M 0.36M 1.57M
Cash flows other operating - - - -3.05M 0.17M
Cash and cash equivalents changes - - - 9.89M -324.74M
Change in working capital 2.77M 9.16M -0.59M 3.02M 2.83M
Stock based compensation 17.59M 22.58M 17.26M 18.83M 15.91M
Other non cash items -5.12M -7.02M -4.12M 0.51M 1.22M
Free cash flow -146.72M -104.51M -83.73M -82.43M -52.27M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
OLMA
Olema Pharmaceuticals Inc
-
-%
7.02 - - - 2.09 -3.33
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

780 Brannan Street, San Francisco, CA, United States, 94103

415 651 3316

150

Name Title Year Born
Dr. Sean P. Bohen M.D., Ph.D. Pres, CEO & Director 1967
Mr. Shane William Charles Kovacs M.B.A. Chief Operating & Financial Officer 1974
Dr. Cyrus L. Harmon Ph.D. Chief Research Officer & Director 1971
Mr. Kinney Horn Chief Bus. Officer 1974
Dr. Peter J. Kushner Ph.D. Co-Founder & Sr. Research Fellow 1939
Ms. Courtney Dugan VP of Investor Relations & Communications NA
Mr. John B. Moriarty Jr. Exec. VP, Chief Legal Officer & Corp. Sec. 1968
Ms. Julie Dexter VP & Head of People NA
Dr. David C. Myles Ph.D. Chief Discovery & Non-Clinical Devel. Officer 1963
Ms. Demiana Faltaos Ph.D., Pharm.D. VP & Head of Clinical Pharmacology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…